Telomir Pharmaceuticals (NASDAQ: TELO) has announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that its lead compound, Telomir-Zn, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The findings, which include reduced oxidative stress, lower hepatic copper burden, and improved liver function markers, provide strong support for the biological activity of Telomir-Zn in this indication and expand the company’s scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation.
Wilson’s disease is a rare genetic disorder characterized by excessive copper accumulation in the liver and other organs, leading to oxidative stress, liver damage, and neurological symptoms. Current treatments focus on chelation therapy to remove copper, but they often have limited efficacy and significant side effects. The preclinical results suggest that Telomir-Zn may offer a novel therapeutic approach by modulating intracellular metal homeostasis and redox balance.
According to the press release, the study showed that Telomir-Zn treatment resulted in statistically significant improvements in survival rates and reductions in hepatic copper levels compared to untreated controls. Additionally, markers of oxidative stress were decreased, and liver function tests indicated reduced damage. These effects were dose-dependent, with higher doses providing greater benefits.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Telomir-Zn, the company’s lead program, has previously demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The publication of these data in a peer-reviewed journal adds credibility to the company’s scientific approach and may pave the way for future clinical development in Wilson’s disease. For more details on the study, the full press release can be accessed at https://ibn.fm/fOSNo. Investors seeking the latest news and updates about TELO can visit the company’s newsroom at https://ibn.fm/TELO.
